Form 4: Helix Acquisition Corp. II Executive Reports Stock Transacti
Insider Transaction (Form 4)
Yong Ben, Chief Med & Dev Officer of Helix Acquisition Corp. II, reported a transaction in 1,047 shares of common stock on October 1, 2026.
Summary
- Tax/exercise-price withholding: disposed of 1,047 Common Stock at $3.94 ($4,125) on October 1, 2026; holds 43,529 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Yong Ben — Officer (Chief Med & Dev Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Tax/exercise-price withholding | Common Stock | 1,047 | $4 | $4.1K | 43,529 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Tax/exercise-price withholding (1,047 shares) |
Keywords
insider transaction, Form 4, BBOT, BridgeBio Oncology Therapeutics, Inc., neutral, Yong Ben
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.